drugset / Trial / NCT01778244

Metformin for Treatment of Antipsychotic-induced Dyslipidemia

NCT01778244 ↗

Phase 4 Completed 162 enrolled Central South University
RandomizedFactorialQuadruple-blindTreatment

Summary

Almost all antipsychotics can induce dyslipidemia, but no treatment has been established. Metformin can improve lipid levels in obese patients. The investigators conducted a randomized, placebo-controlled study to test the efficacy of metformin for antipsychotic-induced dyslipidemia.

Timeline

Start
2008-11
Primary completion
2011-12
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg —

Indications